Close



Apr 23, 2024 06:00AM
Apr 23, 2024 06:00AM
Mar 14, 2024 04:30PM
Mar 14, 2024 04:28PM
Mar 14, 2024 10:12AM
Mar 8, 2024 06:08AM
Mar 7, 2024 05:19PM BeiGene (BGNE) Announces FDA Accelerated Approval of BRUKINSA
Mar 7, 2024 05:19PM
Feb 29, 2024 10:02AM
Feb 27, 2024 06:02AM
Feb 27, 2024 06:00AM
Feb 26, 2024 06:00AM
Feb 26, 2024 05:49AM
Feb 26, 2024 05:00AM BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Dec 22, 2023 06:00AM
Dec 22, 2023 06:00AM
Nov 9, 2023 04:01PM
Oct 17, 2023 04:02PM
Oct 17, 2023 04:01PM
Oct 17, 2023 04:01PM
Oct 16, 2023 06:00AM BeiGene Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeline Assets
Sep 19, 2023 06:15AM
Sep 19, 2023 06:15AM
Aug 2, 2023 06:00AM
Jul 12, 2023 07:03AM
Jul 12, 2023 07:00AM
May 4, 2023 07:00AM
Apr 20, 2023 07:03AM BeiGene (BGNE) Announces Positive Phase 3 Tislelizumab Trial Results
Apr 20, 2023 07:00AM
Apr 17, 2023 02:32PM
Apr 17, 2023 02:32PM
Apr 17, 2023 02:30PM
Apr 17, 2023 02:30PM
Mar 21, 2023 07:01AM
Mar 21, 2023 07:00AM BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
Mar 16, 2023 04:15PM
Feb 27, 2023 07:00AM
Feb 24, 2023 07:02AM
Feb 24, 2023 07:00AM
Jan 19, 2023 05:03PM
Jan 19, 2023 04:42PM
Dec 13, 2022 10:01AM BeiGene's (BGNE) BRUKINSA Demonstrated Superior PFS Over IMBRUVICA in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
Dec 13, 2022 10:00AM
Dec 8, 2022 02:11PM
Dec 8, 2022 02:10PM
Nov 9, 2022 07:00AM
Nov 3, 2022 09:00AM
Oct 13, 2022 06:39AM
Oct 12, 2022 07:04AM BeiGene (BGNE) Announces Positive Topline Results from Final PFS Analysis of BRUKINSA Compared to IMBRUVICA in Phase 3 CLL Trial
Oct 12, 2022 07:00AM

251,899 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All